Clinical Trial Update: AZD6765 for Treatment Resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 trial of AZD6765 for treatment-resistant depression has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• AZD6765 (lanicemine)

Snippet

Sponsor: AstraZeneca | Conditions: Depression | Phase 2 | Status: COMPLETED